Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $16.05 million. The enterprise value is -$5.14 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 5.35 million shares outstanding. The number of shares has increased by 2.90% in one year.
| Current Share Class | 5.35M |
| Shares Outstanding | 5.35M |
| Shares Change (YoY) | +2.90% |
| Shares Change (QoQ) | +6.26% |
| Owned by Insiders (%) | 2.90% |
| Owned by Institutions (%) | 9.15% |
| Float | 5.19M |
Valuation Ratios
The trailing PE ratio is 1,921.82.
| PE Ratio | 1,921.82 |
| Forward PE | n/a |
| PS Ratio | 1.43 |
| Forward PS | 3.41 |
| PB Ratio | 0.76 |
| P/TBV Ratio | 0.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.75, with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.75 |
| Quick Ratio | 14.38 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 0.04% and return on invested capital (ROIC) is -3.45%.
| Return on Equity (ROE) | 0.04% |
| Return on Assets (ROA) | -3.17% |
| Return on Invested Capital (ROIC) | -3.45% |
| Return on Capital Employed (ROCE) | -5.50% |
| Revenue Per Employee | $699,884 |
| Profits Per Employee | $522 |
| Employee Count | 16 |
| Asset Turnover | 0.49 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $681 in taxes.
| Income Tax | 681 |
| Effective Tax Rate | 7.54% |
Stock Price Statistics
The stock price has decreased by -36.97% in the last 52 weeks. The beta is 1.51, so Lipocine's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | -36.97% |
| 50-Day Moving Average | 3.30 |
| 200-Day Moving Average | 4.55 |
| Relative Strength Index (RSI) | 41.61 |
| Average Volume (20 Days) | 11,117 |
Short Selling Information
The latest short interest is 76,442, so 1.43% of the outstanding shares have been sold short.
| Short Interest | 76,442 |
| Short Previous Month | 82,750 |
| Short % of Shares Out | 1.43% |
| Short % of Float | 1.47% |
| Short Ratio (days to cover) | 6.29 |
Income Statement
In the last 12 months, Lipocine had revenue of $11.20 million and earned $8,352 in profits.
| Revenue | 11.20M |
| Gross Profit | 11.20M |
| Operating Income | -1.16M |
| Pretax Income | -8.49M |
| Net Income | 8,352 |
| EBITDA | -1.11M |
| EBIT | -1.16M |
| Earnings Per Share (EPS) | -$0.00 |
Full Income StatementBalance Sheet
The company has $21.63 million in cash and $438,625 in debt, giving a net cash position of $21.19 million or $3.96 per share.
| Cash & Cash Equivalents | 21.63M |
| Total Debt | 438,625 |
| Net Cash | 21.19M |
| Net Cash Per Share | $3.96 |
| Equity (Book Value) | 21.00M |
| Book Value Per Share | 3.93 |
| Working Capital | 20.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.22 million and capital expenditures -$90,086, giving a free cash flow of -$1.31 million.
| Operating Cash Flow | -1.22M |
| Capital Expenditures | -90,086 |
| Free Cash Flow | -1.31M |
| FCF Per Share | -$0.25 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -10.31% and 0.07%.
| Gross Margin | 100.00% |
| Operating Margin | -10.31% |
| Pretax Margin | 0.08% |
| Profit Margin | 0.07% |
| EBITDA Margin | -9.95% |
| EBIT Margin | -10.31% |
| FCF Margin | n/a |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.90% |
| Shareholder Yield | n/a |
| Earnings Yield | 0.05% |
| FCF Yield | -8.17% |
Analyst Forecast
The average price target for Lipocine is $10.00, which is 233.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 233.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 36.22% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 0.0588235:1.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0588235:1 |
Scores
Lipocine has an Altman Z-Score of -0.25 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.25 |
| Piotroski F-Score | 2 |